EDIT vs NTLA
EDIT and NTLA side by side — valuation & fundamentals (public data).
Key statistics
| Metric | EDITEditas Medicine, Inc. | NTLAINTELLIA THERAPEUTICS, INC. |
|---|---|---|
| Market cap | $258.47M | $1.50B |
| P/S | 6.4x | 22.2x |
| Revenue growth (YoY) | 25.4% | 16.9% |
| Earnings growth (YoY) | 32.5% | 20.5% |
| EBIT margin | -394.9% | -651.7% |
| ROE | -3631.1% | -66.5% |
| 1y total return | — | -6.2% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: EDIT vs NTLA
| Metric | EDIT | NTLA |
|---|---|---|
| End value | $880 | $4.9K |
| Total return | -91.2% | -51.3% |
| CAGR | -21.1% | -6.8% |
| Volatility | 83.5% | 78.4% |
| Sharpe | 0.07 | 0.25 |
| Sortino | 0.11 | 0.37 |
| Max drawdown | -98.9% | -96.5% |
Based on 2574 common trading days, 2016-05-06 → 2026-08-03 · risk-free 3.91% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)